|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's Range||110.25 - 111.25|
|52 Week Range||34.53 - 114.20|
|Beta (3Y Monthly)||2.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||104.97|
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it will serve as the inaugural sponsor of Believe Limited’s first-ever science fair, which will be hosted at the National Hemophilia Foundation’s 71st Bleeding Disorders Conference, Oct. 3 – 5, 2019, in Anaheim, CA. The Science Fair™ will educate children and adults with hemophilia as well as other attendees about the science behind bleeding disorders in a number of engaging ways.
By John Miller ZURICH (Reuters) - Swiss drugmaker Roche lifted its 2019 outlook on Wednesday, as sales growth in China and the United States outpaced price declines it has suffered amid President Donald ...
Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spark Therapeutics, Inc. (“Spark” or the “Company”) (ONCE) in connection with the proposed sale of Spark to Roche Holdings, Inc. (“Roche”). If you are a Spark shareholder and would like to discuss your legal rights and options, please visit Spark (ONCE) Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or email@example.com or firstname.lastname@example.org. The lawsuit alleges that Defendants issued a materially misleading proxy statement recommending that Spark shareholders tender their shares to Roche.
Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
NEW YORK, NY / ACCESSWIRE / April 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that complaints have been filed on behalf of shareholders of ...
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
WILMINGTON, Del., April 04, 2019 -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District.
** Malaysia will sell a superyacht allegedly bought with stolen funds from state fund 1MDB to casino operator Genting Malaysia Bhd for $126 million, in the first major asset sale by Kuala Lumpur to recover billions lost from the fund. ** Saudi Arabia's AlRajhi Holding Group and Dubai's Al Ghurair have teamed up in a consortium to bid for Saudi Arabian state grain buyer SAGO's flour mills, three sources familiar with the matter told Reuters. ** Deutsche Bank and Commerzbank are divided over the pace of their merger talks, two people with knowledge of the matter said.
Roche received offers representing about 29 percent of Sparks’s outstanding shares before the deadline was extended.
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Roche (RHHBY) withdraws its Premerger Notification and Report Form in connection with the pending acquisition of Spark Therapeutics.
In a press release, the Swiss company confirmed on Wednesday it will be extending its offer to May 2 from the original deadline of Wednesday, April 3, after receiving support for its takeover deal from less than 30% of Spark shareholders. Roche also said a review of the acquisition by the U.S. Federal Trade Commission, the government agency which seeks to prevent anti-competitive practices, was taking more time than anticipated and its plans had had to be refiled. "All terms and conditions of the offer shall remain unchanged during the extended period," Roche said in a statement on the $114.50 per share offer it announced in February.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it. A spokesman said Roche remained confident the deal would be completed by the end of June. "All terms and conditions of the offer shall remain unchanged during the extended period," Roche said in a statement on the $114.50 per share offer it announced in February.
European shares rose for the fourth straight session on Wednesday, as investors took heart from further signs of recovery in China and progress towards a possible trade deal between Beijing and Washington. White House economic adviser Larry Kudlow said on Tuesday he expects the United States and China "to make more headway" as the two sides resume trade talks this week. Strong economic data out of China has also helped sentiment.
OTCQX: RHHBY) and Spark Therapeutics, Inc. (ONCE) ("Spark") today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the "HSR Act") in connection with Roche`s pending acquisition of Spark. Roche and Spark both filed a Premerger Notification and Report Form under the HSR Act on March 1, 2019 with respect to the pending acquisition. On March 18, 2019, Roche withdrew the March 1, 2019 filing and refiled a Premerger Notification and Report Form.
Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing
Biogen Inc (NASDAQ: BIIB ) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE ). Roche Holdings AG Basel ADR (OTC: RHHBY ) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE ). Sarepta ...
NEW YORK , March 22, 2019 /PRNewswire/ -- AVEO Pharmaceuticals, Inc. (AVEO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the FDA seeking additional ...
The groundwork for the proposed $4.8 billion sale of Philadelphia gene therapy pioneer Spark Therapeutics to Roche actually began last spring and would eventually involve three potential suitors, according to documents filed with Securities and Exchange Commission related to the proposed transaction. Founded in 2013 when it was spun out of Children's Hospital of Philadelphia, Spark earned the distinction of being the first company to received Food and Drug Administration approval for gene therapy to treat a genetic disease. May 2018 to August 2018: Spark engages in discussions Roche Holdings and two other undentified global biotechnology and pharmaceutical companies regarding a potential hemophilia A collaboration. December 2018.
Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.